Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03619083 · ClinicalTrials.gov registry record
Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer
A clinical trial of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 187
- Enrollment target
- 1
- Study location
NCT03619083: Active study of Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03619083 is a study of Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 187 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03619083, a study of Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 187 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to find out if a new series of evaluations called the SAE (Sensory-Attention-Executive) Battery can help researchers learn more about how cancer treatment does or does not change the way the brain processes/filters information, emotions, attention span, and behavior by comparing the results of the SAE Battery with traditional evaluations like questionnaires.
Primary Outcome
using the Sensory-Attention-Executive Battery
Conditions Studied
Interventions
- BEHAVIORAL Assessments
- OTHER SAE battery
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2027-07 |
What the registry record for NCT03619083 still lists
NCT03619083 is an observational study that tracks outcomes without assigning an intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Assessments is the first listed.
NCT03619083 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03619083 about?
NCT03619083 is a clinical study titled "Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer". This study is being done to find out if a new series of evaluations called the SAE (Sensory-Attention-Executive) Battery can help researchers learn more about how cancer treatment does or does not change the way the brain processes/filters information, emotions, attention span, and behavior by compa...
What is the current status of trial NCT03619083?
This trial is currently active not recruiting. The enrollment target is 187 participants. The study started on 2018-07-13. Estimated completion is 2027-07.
What conditions does trial NCT03619083 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03619083?
The interventions under investigation include: Assessments (BEHAVIORAL), SAE battery (OTHER).
Who is sponsoring clinical trial NCT03619083?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03619083 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03619083's enrollment target sits among peer trials
187 394th of 1224 higher than 830 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06153251 · 187 participants · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI